2,3-dihydro-1-(4-fluorophenyl)-4-methyl-1H-pyrrolo<2,3-b>pyrido<1,2-a>benzimidazole-5-carbonitrile

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,3-dihydro-1-(4-fluorophenyl)-4-methyl-1H-pyrrolo<2,3-b>pyrido<1,2-a>benzimidazole-5-carbonitrile
• 英文别名: 1-(4-Fluorophenyl)-4-methyl-2,3-dihydro-1H-pyrrolo[3',2':5,6]pyrido[1,2-a]benzimidazole-5-carbonitrile；3-(4-fluorophenyl)-7-methyl-1,3,10-triazatetracyclo[7.7.0.02,6.011,16]hexadeca-2(6),7,9,11,13,15-hexaene-8-carbonitrile
• 化学式: C₂₁H₁₅FN₄
• 分子量: 342.375
• InChiKey: BQKJBAPBSRNLCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  44.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氰甲基苯并咪唑 在 乙酸铵 、 氯化亚砜 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 、 苯 为溶剂， 反应 9.0h， 生成 2,3-dihydro-1-(4-fluorophenyl)-4-methyl-1H-pyrrolo<2,3-b>pyrido<1,2-a>benzimidazole-5-carbonitrile
  参考文献：
  名称：

  Benzimidazole condensed ring system. IX. Potential antineoplastics. New synthesis of some pyrido[1,2-α]benzimidazoles and related derivative

  摘要：

  Some pyrido[1,2-a]benzimidazoles were prepared in order to investigate their in vitro antineoplastic and anti-HIV activities. Two compounds (9b, NSC 658526 and 15, NSC 664715) showed a variable degree of antineoplastic activity against some of the cell lines tested. Compound 9a (NSC 649900) exhibited a good in vitro antineoplastic activity with subpanel disease selectivity, particularly against most of the cell lines of leukemia and some cell lines from colon, melanoma and renal cancer panels.

  DOI：

  10.1016/0223-5234(96)88241-9

文献信息

• Benzimidazole condensed ring system. IX. Potential antineoplastics. New synthesis of some pyrido[1,2-α]benzimidazoles and related derivative
  作者：E Badawey、T Kappe

  DOI：10.1016/0223-5234(96)88241-9

  日期：1995.1

  Some pyrido[1,2-a]benzimidazoles were prepared in order to investigate their in vitro antineoplastic and anti-HIV activities. Two compounds (9b, NSC 658526 and 15, NSC 664715) showed a variable degree of antineoplastic activity against some of the cell lines tested. Compound 9a (NSC 649900) exhibited a good in vitro antineoplastic activity with subpanel disease selectivity, particularly against most of the cell lines of leukemia and some cell lines from colon, melanoma and renal cancer panels.